Biomab Report: Analysis of Market Opportunities and Challenges

This report provides an analysis of the Biomab market, focusing on the opportunities and challenges faced by the company. It highlights the limited current market due to the high cost of the drug, but suggests potential for growth with advancements in research and potential price stabilization. The report discusses the challenges of obtaining drug approvals in different countries, using India as an example, where affordability is a significant issue despite a large potential market. The report also touches upon the off-label drug sales and the importance of market perception. The analysis concludes with a reflection on the current opportunities and the future prospects for Biomab. The report includes references to relevant research papers.

Accounting
Assignment

By student name
Professor
University
Date: 19TH April 2019.
Page 1

Table of Contents
Analysis...................................................................................................................... 3
References................................................................................................................. 4
Page 2

Analysis
The present market for Biomab is limited given that many patients cannot afford
the drug, as it is very costly, but with changes in the market scenarios and research
in the field of medication, there are chances that the prices will become more stable
and that will help in supporting many cancer patients. The major issue that Biomab
is facing is getting approval for the sale of drugs in different countries. For example,
in a country like India even if it gets the approval there are some issues that the
company has to face, as the affordability of these drugs is very limited. Given the
overall population of India is so huge, the present market opportunity with Biomab
is that they are focusing on the head and tail of the cancer patients in India (Fauvel
& Yasri, 2014). These patients would be marked officially to use these drugs based
on their power to afford the same. The drug would be marketed to them and the
current estimate of these patients is 1900 patients. In India there is a huge market
that sale drug off the label and thus they target more patients than those that are
official marked to consume these drugs. So, we see a lot depends on how these
drugs are being sold and in which market are they being perceived the best. All this
will affect the future of Biomab in India and other economies too (Chortkoff &
Stenehjem, 2019) So it can be said that present opportunity is not that great but in
future with research their might be more opportunities.
Page 3

References
Chortkoff, B. & Stenehjem, D., 2019. 38 - Chemotherapy, Immunosuppression, and
Anesthesia. Pharmacology and Physiology for Anesthesia, 3(1), pp. 753-768.
Fauvel, B. & Yasri, A., 2014. Antibodies directed against receptor tyrosine kinases.
mAbs, 6(4), pp. 838-851.
Page 4